UCT-01-097 + gemcitabine + paclitaxel

UCT-01-097 + gemcitabine + paclitaxel is an experimental combination regimen under investigation for the treatment of advanced solid tumors. UCT-01-097 is a novel, potent, and selective small molecule inhibitor of ERK1/2, key kinases in the MAPK pathway, developed to overcome resistance to upstream MAPK pathway inhibitors and provide anti-tumor activity in cancers dependent on ERK signaling[3]. Gemcitabine is a nucleoside analog chemotherapeutic agent that inhibits DNA synthesis, while paclitaxel stabilizes microtubules and inhibits mitosis. Both gemcitabine and paclitaxel are established antineoplastic agents that, when used together, have demonstrated synergistic effects and improved clinical outcomes in multiple tumor types[2][4][6][8]. The combination of these three agents is designed to enhance anticancer efficacy through simultaneous targeting of cellular signaling (UCT-01-097) and cell division (gemcitabine and paclitaxel). A first-in-human, phase 1 clinical study was conducted to assess safety, tolerability, pharmacokinetics, and anti-tumor activity of UCT-01-097 with or without other agents in advanced solid tumors, but the trial was terminated[1][7].